Research of Intensive Treatment in Hormone Receptor<10% & Human Epidermal

Updated 05/03/2024

Status Recruiting

Clinical Trial Summary

This is a phase IV, single-center, prospective, open-label, randomized,controlled study

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03270007
Study type	Interventional
Source	Peking University
Contact	Xing Wang, MD
Phone	0086-10-88271119
Email	wangxing_susu@sina.com
Status	Recruiting
Phase	Phase 4
Start date	November 10, 2017
Completion date	December 31, 2024

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05923177` - Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3	Phase 1
	Completed	`NCT01033162` - Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care	N/A
	Completed	`NCT00527449` - Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel	Phase 2
	Completed	`NCT04468113` - Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
	Recruiting	`NCT03711877` - Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)	Phase 3
	Active, not recruiting	`NCT01019616` - Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy	Phase 3
	Completed	`NCT04127019` - Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)	Phase 3
	Completed	`NCT01314833` - Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy	Phase 3
	Terminated	`NCT00172068` - Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow	Phase 2
	Completed	`NCT01049425` - Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer	Phase 3
	Recruiting	`NCT01840293` - Breast Cancer Proteomics and Molecular Heterogeneity
	Completed	`NCT01779479` - Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)	Phase 2
	Completed	`NCT04277338` - Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3	Phase 1
	Recruiting	`NCT05445050` - mULM to Support Breast Cancer Diagnosis and Therapy	N/A
	Completed	`NCT00793377` - Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer	Phase 3